PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Completes Quarterly Dividend Payment
PDL BioPharma to Present at the Jefferies 2016 Healthcare Conference
PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
PDL BioPharma Announces First Quarter 2016 Financial Results
PDL BioPharma Announces 2016 Second Quarter Dividend